ASX:OCC Orthocell (OCC) Stock Price, News & Analysis → Bible Shocker: Have You Seen Elon Musk’s Miracle? (From InvestorPlace) (Ad) Free OCC Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume669,530 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Orthocell alerts: Email Address Ad Crypto 101 MediaThe Overlooked Retirement Asset You Probably Don’t Own4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm.Click here to access the Crypto Retirement Blueprint now. About Orthocell Stock (ASX:OCC)Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia. The company offers CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons, and cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation to treat articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental procedure; and Remplir, a collagen scaffold used in peripheral nerve repair. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.Read More Ad Crypto 101 MediaThe Overlooked Retirement Asset You Probably Don’t Own4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm.Click here to access the Crypto Retirement Blueprint now. OCC Stock News HeadlinesMarch 26, 2024 | proactiveinvestors.comOrthocell moves closer to US market clearance and salesFebruary 29, 2024 | morningstar.comOrthocell Ltd OCCFebruary 22, 2024 | proactiveinvestors.comOrthocell raising $3.5 million; adds heavy hitters to registerJanuary 15, 2024 | finance.yahoo.comOrthocell (ASX:OCC) shareholders have earned a 23% CAGR over the last five yearsJanuary 14, 2024 | au.investing.comOrthocell appoints former Deputy Prime Minister Kim Beazley as a directorNovember 13, 2023 | proactiveinvestors.comOrthocell tendon cell therapy as effective as surgery for chronic tennis elbowNovember 1, 2023 | finance.yahoo.comOrthocell on the cusp of significant growthOctober 29, 2023 | proactiveinvestors.com.auOrthocell and University of Western Australia cement long-term partnership through equity exchangeOctober 29, 2023 | proactiveinvestors.comOrthocell and University of Western Australia cement long-term...October 25, 2023 | finance.yahoo.comOrthocell Limited's (ASX:OCC) CEO Will Probably Find It Hard To See A Huge Raise This YearAugust 23, 2023 | proactiveinvestors.com.auOrthocell has Striate+™ re-certified under stricter European medical device regulationsAugust 6, 2023 | au.investing.comBiotechs play the long game as always in a healthy June quarterMay 28, 2023 | proactiveinvestors.com.auOrthocell thrilled to welcome John Van Der Wielen as chairmanMay 28, 2023 | proactiveinvestors.comOrthocell appoints experienced executive John Van Der Wielen as independent non-executive chairmanMay 25, 2023 | finance.yahoo.comOCC.AX - Orthocell LimitedApril 17, 2023 | proactiveinvestors.com.auOrthocell kicks off comparator study for nerve repair device RemplirMarch 30, 2023 | finance.yahoo.comOrthocell welcomes globally recognised nerve surgeons to advisory boardMarch 28, 2023 | proactiveinvestors.comOrthocell appoints specialist US-based nerve surgeons to medical advisory boardMarch 7, 2023 | proactiveinvestors.com.auOrthocell welcomes high profile US-based healthcare specialist to the boardMarch 7, 2023 | proactiveinvestors.com.auOrthocell appoints US healthcare specialist as independent non-executive directorMarch 3, 2023 | finance.yahoo.comOrthocell First Half 2023 Earnings: AU$0.021 loss per share (vs AU$0.024 loss in 1H 2022)February 26, 2023 | finanznachrichten.deThe Options Clearing Corporation: OCC Welcomes Jefferies Executive Joseph Lewis to Board of DirectorsFebruary 8, 2023 | finance.yahoo.comOrthocell (ASX:OCC) shareholders have earned a 4.7% CAGR over the last five yearsNovember 1, 2022 | proactiveinvestors.com.auOrthocell’s Remplir™ added to Australian Prostheses listNovember 1, 2022 | msn.comASX Biotech Stocks: Surgeons can now be reimbursed for using Orthocell’s nerve repair deviceSee More Headlines Receive OCC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Orthocell and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:OCC CUSIPN/A CIKN/A Webwww.orthocell.com.au Phone61 8 9360 2888FaxN/AEmployees317Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,420,000.00 Net Margins-154.57% Pretax MarginN/A Return on Equity-177.01% Return on Assets-26.69% Debt Debt-to-Equity Ratio34.88 Current Ratio4.60 Quick Ratio5.07 Sales & Book Value Annual Sales$4.80 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow3.41 Book ValueA$0.01 per share Price / BookN/AMiscellaneous Outstanding Shares209,330,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.11 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Paul Frederick Anderson (Age 58)CEO, MD & Executive Director Comp: $650.97kMs. Nicole Jane TelfordChief Financial OfficerMr. Alex McHenryChief Operating OfficerProf. Ming Hao ZhengChief Scientific Officer and Member of Medical & Scientific Advisory BoardMr. Tony MacintyreChief Manufacturing OfficerMr. Peter Gordon Webse B.Bus (Age 61)FCIS, FCPA, FGIA, M.A.I.C.D., Company Secretary More ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersJohn WielenBought 20,000 shares on 4/24/2024Total: $7,620.00 ($0.38/share)John WielenBought 35,000 shares on 4/15/2024Total: $13,650.00 ($0.39/share)Kim Beazley ACSold 2,000,000 sharesTotal: $820,000.00 ($0.41/share)Fiona WoodSold 2,000,000 sharesTotal: $820,000.00 ($0.41/share)John WielenSold 250,000 sharesTotal: $91,250.00 ($0.37/share) OCC Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Orthocell own? Based on aggregate information from My MarketBeat watchlists, some companies that other Orthocell investors own include Plug Power (PLUG), Viralytics (VRACY), Genetic Technologies (GTG) and GP Strategies (GPX). This page (ASX:OCC) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingShocking $16T Elon Musk Crypto LeakCrypto 101 MediaForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsDems have chosen Biden replacement?Paradigm PressHow Biden has already won 2024Porter & CompanyExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersA letter is coming from the "Bureau of the Fiscal Service".Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orthocell Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.